REAL-TIME ANALYZERS INC — Department of Defense SBIR Phase I: CBD181-006
REAL-TIME ANALYZERS INC — SBIR Phase I award from Department of Defense.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Defense in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $149,999. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code CBD181-006 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $149,999
- Agency
- Department of Defense · Office for Chemical and Biological Defense
- Program / Phase
- SBIR · Phase I
- Topic
- CBD181-006
- Solicitation
- 18.1
- NAICS
- —
- Place of performance
- CT
- Period
- 2018-10-15 → 2019-04-14
Description
While this solicitation describes the need for better sampling methods and more rugged mass spectrometers to meet this DoD requirement, the topic author agreed to consider our alternative approach, which employs existing DoD Raman spectrometers. The goal of this proposed project (through Phase III) is to develop a Field-Usable Designer Drug Analyzer capable of identifying and quantifying drugs in saliva and blood at 10 ng/mL in 10 minutes. Feasibility will be demonstrated during Phase I by developing a novel sample system that separates drugs from saliva and blood for analysis by Raman spectroscopy. The analyzer detection limits and measurement time will be quantified by measuring aspirin, codeine and fentanyl in both saliva and blood samples. The goal of the Phase II project is to design and build a sample cartridge and interface that attaches to existing DoD Mil-Std 810G hand-held Raman spectrometers. It will be used to measure ~50 drugs in saliva and blood. The analyzer and cartridge will be validated by comparing measurements of real saliva and blood samples containing highly potent drugs, such as fentanyl and synthetic cannabinoids, with clinical laboratory measurements performed through an existing partnership with Yale University and the local Veterans Affairs Medical Center.